A drug candidate dubbed Aes-103 that was developed by researchers at the US National Institute of Health's National Center for Advancing Translational Sciences has been acquired by Baxter International's BioScience business.

According to NIH, Aes-103 was developed to target the underlying molecular mechanism of sickle cell disease, and Baxter will now usher the drug through the next stages of clinical development with an eye toward obtaining regulatory approval and commercializing the drug.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.